Cannabis Lozenge Patent Issued to Cannabis Sativa, Inc. by Us Patent & Trademark Office

MESQUITE, NV / ACCESSWIRE / October 25, 2018 / Cannabis Sativa, Inc. (CBDS) is pleased to announce that on October 23, 2018, the United States Patent Office issued US Patent number 10105343 titled “Cannabis based compositions and methods of treating hypertension” to Cannabis Sativa”. The marijuana lozenge invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage.

“CBDS acquired the rights to certain pending IP in a stock based, multimillion dollar agreement in 2014”, said President David Tobias. “ Cannabis Sativa envisioned substantial value in the pending intellectual property which now granted, gives Cannabis Sativa the opportunity to standardize a marijuana product as well as a marijuana strain and position itself firmly in the marketplace”. “To that end, Cannabis Sativa has hired top notch, highly credible industry consultants in an effort to develop the best branding and packaging to launch the now patented cannabis lozenge in California”, Tobias concluded.

The marijuana lozenge patent follows the patent issuance of the Ecuadorian Sativa marijuana strain by the USPTO on December 20, 2016.

About Cannabis Sativa, Inc.:

Cannabis Sativa, Inc. (''CBDS'') is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the ''hi'' and ''White Rabbit'' brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: PrestoDoctor® (https://prestodoctor.com), Wild Earth Naturals®, (https://wildearthnaturals.com/), and iBudtender (https//:ibudtender.com). In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.

Forward-Looking Statements:

This press release contains ''forward-looking statements.'' Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact Information:

Investor Relations
1646 West Pioneer Blvd Suite 120
Mesquite, NV 89027
702-346-3906
http://www.cannabissativainc.com

SOURCE: Cannabis Sativa, Inc.